Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies

Table 1 Patient characteristics

	n (%)	PCI median
Females	47 (78.3)
BMI (kg/m2; median)	26
Synchronous PM	26 (43.3)
Neoadjuvant chemotherapy	18 (69.2)
Adjuvant chemotherapy	22 (84.6)
Both	17 (65.4)
Metachronous PM	34 (56.7)
Neoadjuvant chemotherapy	8 (23.5)
Adjuvant chemotherapy	24 (70.6)
Both	3 (8.8)
ASA
1	17 (28.3)
2	34 (56.7)
3	9 (15)
PCI (median)	13
Primary origin of neoplasia
Uterus	21 (35)	13
Breast	8 (13.4)	19
Sarcoma	5 (8.4)	16
Small bowel	6 (10)	14
Liver	4 (6.6)	9
Pancreas	4 (6.6)	8
Biliary tract	3 (5)	2
MPM	3 (5)	12
Miscellaneous1	6 (10)	7.5

¹Miscellaneous includes: Ovarian carcinosarcoma; gastrointestinal stromal tumor (previously treated with TKI, resistant); 2 jejunal NET; desmoplastic small round cell tumor; malignant Pheochromocytoma.

BMI: Body mass index; PM: Peritoneal metastases; PCI: Peritoneal Cancer Index; MPM: Malignant peritoneal mesothelioma.

Table 2 Post-operative complication according to Clavien-Dindo classification

Clavien-Dindo	n (%)	LOS day median	LOS day median
0	11 (18.4)	9	14
1	4 (6.6)	10
2	31 (51.7)	16
31	10 (16.7)	23	22
42	3 (5)	15
5	1 (1.6)	13

¹3A = 6 patients; 3B = 4 patients.

²All 4A.

LOS: Length of hospital stay.

Table 3 Multivariable Cox regression by primary tumor site

Primary tumor site	HR	95%CI	P value
Breast cancer (reference)	1.00	-	-
Small bowel	25.21	3.53-180.14	< 0.005
Biliary tract	32.53	4.22-250.70	< 0.005
Pancreas	24.34	1.62-365.44	0.021
Uterus	6.71	1.72-26.11	0.006
Sarcoma	2.38	0.46-12.34	0.30
MPM	1.33	0.30-5.83	0.70
Miscellaneous	1.05	0.32-3.38	0.94

Miscellaneous includes: Ovarian carcinosarcoma; gastrointestinal stromal tumor (previously treated with TKI, resistant); 2 jejunal NET; desmoplastic small round cell tumor; malignant Pheochromocytoma. HR: Hazard ratio; 95%CI: 95% confidence interval; MPM: Malignant peritoneal mesothelioma.